A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201)
Low-grade serous ovarian cancer is a rare type of ovarian cancer that often grows slowly but does not always respond well to standard chemotherapy. This phase 2 trial, known as RAMP 201, is looking at whether two new targeted medicines can offer a better option when the cancer comes back. The trial tests a drug called avutometinib, taken either on its own or together with another medicine called defactinib. These drugs work by blocking specific signals that cancer cells need to multiply and survive. Researchers want to find out how well these medicines shrink tumours and control the disease, as well as monitor any side effects. The results could help doctors understand which treatment works best for women facing recurrent low-grade serous ovarian cancer.
At a glance
What is this study about?
Low-grade serous ovarian cancer is an uncommon form of ovarian cancer. It tends to grow more slowly than other types, but it can be hard to treat because standard chemotherapy does not always shrink the tumours effectively. When this cancer returns after previous treatment, doctors need better, more targeted options to keep it under control.
This clinical study, called RAMP 201, investigates two newer medicines named avutometinib and defactinib. These medicines are targeted treatments, which means they are designed to seek out and block specific proteins inside cancer cells that tell them to grow. By disrupting these signals, the drugs may help shrink tumours or stop them from getting bigger.
The main aim of the trial is to see how well avutometinib works on its own compared to when it is combined with defactinib. Specialists will look closely at scan results to measure changes in tumour size. They will also track how long any improvements last and keep a close eye on patient safety and quality of life.
Key takeaways
- Tests new targeted medicines for low-grade serous ovarian cancer that has returned.
- Compares avutometinib on its own against avutometinib combined with defactinib.
- Aimed at adult women aged 18 and older.
- A phase 2 study designed to measure tumour shrinkage and safety.
- Participation is entirely voluntary and you can stop at any time.
Who may be eligible?
This trial is open to adult women aged 18 and over who have been diagnosed with low-grade serous ovarian cancer that has returned after previous treatments.
Because this is a specialised study, patients will need to have confirmed low-grade disease rather than the more common high-grade type. The cancer must also be measurable on medical scans so the trial team can track whether the treatment is working.
Women who are pregnant, breastfeeding, or who have other serious health problems—such as severe heart, liver, or kidney conditions—may not be able to join. Your hospital doctor or oncologist can check your medical history to see if you meet all the safety rules.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a woman aged 18 or older.
- I have been diagnosed with low-grade serous ovarian cancer.
- My cancer has returned or progressed following prior cancer treatment.
- I am well enough to attend regular hospital appointments and scans.
- I am not currently pregnant or breastfeeding.
What does participation involve?
If you take part, you will receive either avutometinib alone or avutometinib combined with defactinib. The trial team will give you a clear schedule explaining how and when to take your study medication, which usually comes in capsule or tablet form.
You will need to attend regular clinic appointments for health checks. These visits will include blood tests, physical examinations, and heart tests to check your overall health. You will also have regular CT or MRI scans so doctors can measure your tumours and see how the cancer is responding.
You can remain on the study treatment for as long as your cancer stays stable and any side effects remain manageable. After you finish the treatment, the study team will continue to check on your recovery and general health through routine follow-up visits or phone calls.
Potential risks and benefits
Locations (4)
- —UnverifiedBelgium
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedItaly
Common questions
What is the RAMP 201 trial?
It is a phase 2 study testing whether two targeted medicines, avutometinib and defactinib, can shrink or control recurrent low-grade serous ovarian cancer.
Is this chemotherapy?
No, these are targeted therapies. Unlike standard chemotherapy, which affects rapidly dividing cells generally, targeted drugs aim to block specific growth signals inside cancer cells.
Will I have to pay to take part?
No, the study medication and trial-related tests are provided free of charge, and some travel expenses may be reimbursed depending on the hospital site.
Can I leave the trial if I change my mind?
Yes, you can leave the study at any point for any reason, and your regular medical team will continue to look after you with other treatment options.
How will the doctors know if the treatment is working?
You will have regular scans, such as CT or MRI scans, to measure your tumours and see if they have shrunk, stayed the same, or grown.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.